The PacBio Sequel for Single Molecule, Real-Time, Long Read Sequencing

项目摘要 我们正在申请资金购买PacBio Sequel长读单分子测序仪， 最新的下一代测序仪，于2015年9月发布。该系统将 放置在纽约大学Langone医学中心的基因组技术中心（GTC） （NYULMC），由协作科学办公室管理的共享资源，由 经验丰富和训练有素的工作人员。GTC由专家Adriana Heguy博士领导， 在基因组学领域拥有多年的经验，在合作环境中提供基因组学研究。 目前，GTC仅在我们的三个HiSeq和两个MiSeq上提供短读取序列。我们 没有长时间读取单分子的能力，除了MinION具有非常有限的 吞吐量和能力、高错误率，并且不是行业标准。请求的PacBio 续集将用于满足纽约大学调查人员的大型社区的需求， 和NIH资助的研究项目包括微生物学、宏基因组学、免疫学、寄生虫生物学和 基本的细胞过程，如DNA甲基化和DNA修复，所有这些都需要长时间阅读， 单分子测序这些项目无法用目前的短读技术进行 他们的进展受到了限制，通过其他方法获得长读序测序的机会有限。 机构职能体系PacBio Sequel是满足我们研究人员需求的最佳仪器;它提供了 增加的容量和灵活性，需要更少的空间，并以更低的成本运行， 上一代PacBio RS II系统。重新设计的SMRT流动池基于他们的行业- 标准、成熟的技术，可实现长时间读取、高精度、均匀覆盖和同步 表观遗传特征PacBio Sequel将支持NIH资助的7个主要用户的项目 和6个小用户在纽约大学。主要用户将占据仪器容量的68%; 97%的容量用于 两组的联合使用。所有用户都是NIH资助的。本仪器的任何剩余容量 将分配给试点项目，为赠款提案提供初步数据。我们有丰富 生物信息学和高性能计算能力，已用于PacBio数据分析 和存储。NYULMC致力于通过强大的机构支持尖端基因组学 GTC的支持，以及PacBio Sequel的获取、实施和维护。

PROJECT SUMMARY We are requesting funds to purchase a PacBio Sequel long-read, single molecule sequencer, the latest next-generation sequencing instrument, released in September of 2015. The system will be placed in the Genome Technology Center (GTC) at New York University Langone Medical Center (NYULMC), a shared resource administered by the Office of Collaborative Science and operated by experienced and highly trained staff. The GTC is under the direction of Dr. Adriana Heguy, an expert in genomics with many years of experience providing genomics research in a collaborative setting. Currently the GTC provides only short read sequences on our three HiSeqs and two MiSeqs. We have no long read single molecule capability, with the exception of a MinION which has very limited throughput and capabilities, a high error rate and is not industry-standard. The requested PacBio Sequel will be utilized to fulfill the needs of a large community of NYU investigators with established and NIH funded research programs in microbiology, metagenomics, immunology, parasite biology and basic cellular processes such as DNA methylation and DNA repair, all of which require long-read, single molecule sequencing. These projects cannot be carried out with current short-read technology and their progress has been hampered by limited access to long-read sequencing through other institutions. The PacBio Sequel is the best instrument for the needs of our investigators; it provides increased capacity and flexibility, requires less space and operates at a lower cost as compared to the previous generation PacBio RS II System. The redesigned SMRT flow cell is based on their industry- standard, proven technology for long reads, high accuracy, uniform coverage and simultaneous epigenetic characterization. The PacBio Sequel will support the NIH funded projects of 7 Major Users and 6 Minor Users at NYU. The Major Users will occupy 68% of instrument capacity; 97% capacity for combined usage of both groups. All users are NIH funded. Any remaining capacity of this instrument will be allocated for pilot projects to generate preliminary data for grant proposals. We have extensive bioinformatics and high performance computing capabilities, already enabled for PacBio data analysis and storage. NYULMC is committed to supporting cutting edge genomics through strong institutional support of the GTC, and the acquisition, implementation and maintenance of the PacBio Sequel.